PTIX Profile
Protagenic Therapeutics, Inc., headquartered in New York, New York, is a pioneering biopharmaceutical firm dedicated to advancing the frontier of therapeutics for stress-related neuropsychiatric and mood disorders. Established as a leader in its field, Protagenic focuses on the discovery and development of innovative treatments that address the underlying mechanisms of these debilitating conditions.
At the forefront of its portfolio is PT00114, the company's lead compound. PT00114 is a synthetic version of teneurin carboxy-terminal associated peptide, a naturally occurring brain signaling peptide recognized for its potential to mitigate hyperactive stress responses within the central nervous system. Protagenic's research underscores a commitment to unraveling the intricate biology of stress and mood regulation, offering new hope for patients burdened by these disorders.
Driven by a robust pipeline and a commitment to scientific excellence, Protagenic collaborates closely with leading academic institutions and research centers to advance its therapeutic candidates through rigorous preclinical and clinical development stages. This collaborative approach ensures the translation of cutting-edge scientific discoveries into potential breakthrough therapies that meet the highest standards of safety, efficacy, and regulatory compliance.
Looking ahead, Protagenic Therapeutics remains dedicated to expanding its therapeutic footprint and advancing novel treatment paradigms in neuropsychiatry. With a steadfast focus on innovation and patient-centric research, the company aims to redefine the treatment landscape for stress-related disorders, offering new pathways to wellness and improved quality of life for individuals worldwide.
|
